Crescent Biopharma disclosed options for 31,200 shares to two employees, with a 14.24 exercise price and a 10-year term, approved on September 24, 2026.
Crescent Biopharma, Inc. disclosed a grant of options covering 31,200 shares for two employees, approved on September 24, 2026.
The company’s lead program is a PD-1 x VEGF bispecific antibody.
The options carry an exercise price of 14.24 and an options term of 10.
Source: GlobeNewswire, 25 Sept 2026
Canada's economic calendar includes two low-impact releases: Foreign Securities Purchases, scheduled for August 17, 2026, and the Current Account report, due August 27, 2026. Forecasts point to a rise in foreign securities purchases and a swing to surplus in the current account.
traderpublic Newsroom
The US Goods Trade Balance report is scheduled for release on 2026-08-27T12:30:00.000Z, with analysts projecting a deficit of -99.9B compared with the prior reading of -101.5B. The indicator carries a Low impact rating according to a single report.
traderpublic Newsroom
According to a single report, the USD Natural Gas Storage release scheduled for 2026-08-20T14:30:00.000Z carried a forecast value of 15B against a previous reading of 16B. The indicator's market impact was rated Low, and a subsequent release is scheduled for 2026-08-27T14:30:00.000Z.
traderpublic Newsroom
Federal Reserve Governor Michael S. Barr told a Chicago summit that high prices and rents, plus a housing supply shortfall and lagging incomes, have made shelter unaffordable for many.
traderpublic Newsroom
According to the Federal Reserve Board, the Board issued consent prohibition orders against three former employees for misappropriation, misapplication and conflicts of interest, and check fraud.
traderpublic Newsroom
The European Central Bank's end-June 2026 consolidated dataset shows total assets up 5.18% year on year to €34.99 trillion, an aggregate return on equity of 5.31%, a Common Equity Tier 1 ratio of 16.43% and a non-performing loans ratio of 1.99%.
traderpublic Newsroom
